On September 7, 2022, Arpeggio Biosciences, a preclinical therapeutics company whose technology targets transcriptional dysregulation in disease, announced a $17 million Series A funding round, following a $3.2 million seed round completed in 2020. Funding was led by Builders VC and will support ongoing development of Arpeggio’s drug pipeline, as well as its transcription-monitoring technologies. This Series A funding was also supported by Arpeggio’s seed round investors Khosla Ventures, TechU Ventures, FundersClub, Alice Zhang, and Fifty Years, with new participation from Tencent, ATEM Capital, Formic Ventures, Tau Ventures, Milad Alucozai (BoxOne Ventures), and Matthew De Silva (Longtail Capital). Wilson Sonsini Goodrich & Rosati represented Arpeggio in the transaction and advises the company on ongoing patent, regulatory, and business advisory matters.

Arpeggio's technology combines a proprietary biological assay and machine learning algorithms that together enable rapid, high-resolution snapshots of cellular dynamics following drug treatment. These snapshots are then analyzed to reveal the biological networks that determine a drug’s function and guide therapeutic development. Arpeggio’s technology reads out on transcription directly and can monitor the activity of more than 100,000 transcripts across diseased and healthy cells exposed to diverse stimuli such as small molecules, biologics, or ASOs. Using machine learning, Arpeggio reconstructs the biological networks affected by the molecule and matches the molecule to diseases where the compound could be therapeutically relevant. This Series A funding will enable the company to continue its mission of discovering new therapies for diseases arising through dysregulation of transcription.

The Wilson Sonsini team that advised Arpeggio Biosciences on the transaction included Bill Barrett, James Huie, Ian Edvalson, Vern Norviel, Ryan Isola, Jeremiah I. Nelson, Jesse Schumaker, Sara Patak, and Matthew Garnica.

For more information, please see Arpeggio Biosciences’ press release.